Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F14%3A10227285" target="_blank" >RIV/00216208:11110/14:10227285 - isvavai.cz</a>
Alternative codes found
RIV/00098892:_____/14:#0000842 RIV/00159816:_____/14:00061524 RIV/00064165:_____/14:10227285 RIV/00064173:_____/14:N0000032
Result on the web
<a href="http://dx.doi.org/10.1016/S1474-4422(14)70039-0" target="_blank" >http://dx.doi.org/10.1016/S1474-4422(14)70039-0</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/S1474-4422(14)70039-0" target="_blank" >10.1016/S1474-4422(14)70039-0</a>

Result language
angličtina
Original language name
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial
Original language description
Background In the SELECT trial, disease activity was reduced in patients with multiple sderosis who received dadizumab high-yield process (HYP) for 52 weeks. The primary aim of the SELECTION extension study was to assess the safety and immunogenicity ofextended treatment with dadizumab HYP. This study is registered with ClinicalTrials.gov, number NCT00870740. Findings 517 (91%) of 567 patients who completed the SELECT trial entered SELECTION, of whom 170 were in the treatment initiation group, 173 in the continuous treatment group, and 174 in the washout and re-initiation group. 11 patients in the treatment initiation group (6%), 13 in the continuous treatment group (8%), and ten in the washout and re-initiation group (6%) had any serious adverse event other than relapse of multiple sderosis. One patient in the washout and re-initiation group (300 mg dadizumab HYP) died because of autoimmtme hepatitis; a contributory role of dadizumab HYP could not be exduded. Seven patients tested po
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FH - Neurology, neuro-surgery, nuero-sciences
OECD FORD branch
—

Project
—
Continuities
Z - Vyzkumny zamer (s odkazem do CEZ)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)